The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALZN | -80.69% | N/A | N/A | -100% |
| S&P | +13.35% | +91.49% | +13.87% | +58% |
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
The company hopes to advance the standard of care for people with dementia.
Investors have been driving it lower for over a month now, but the stock just reached a curious price level.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -118.2% |
| Market Cap | $6.52M | 111.9% |
| Market Cap / Employee | $0.93M | 111.9% |
| Employees | 7 | 0.0% |
| Net Income | -$2.70M | -177.4% |
| EBITDA | -$2.67M | -181.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.62M | 370.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -156.14% | 188.0% |
| Return On Invested Capital | -112.43% | 84.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.36M | -106.2% |
| Operating Free Cash Flow | -$2.36M | -123.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.19 | 1.91 | 1.17 | 0.44 | -117.41% |
| Price to Tangible Book Value | -10.04 | 14.24 | 9.98 | 0.44 | -101.93% |
| Enterprise Value to EBITDA | -1.08 | -2.83 | -0.60 | 0.33 | -119.81% |
| Return on Equity | -4408.3% | -1093.0% | -657.2% | -302.2% | -79.70% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
